#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

Apr 13, 2026 · 22h 0m

Ads

Brands

Inserted

Transcript

4k words

Ads in this episode

EP · The Peter Attia Drive · #387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field22:00:01

12:29host read

BetterHelp

betterhelp.com/huberman

13:18host read

Joovv

joovv.com/huberman

45:50host read

AG1

drinkag1.com/huberman

2:01:12inserted

Superhuman

post-roll · Apple client only

Transcript

asr · 3,719 words · docs

0:10Hey everyone, welcome to a sneak peek, Ask Me Anything, or AMA episode of the Drive podcast.

0:16I'm your host, Peter Attia.

0:17At the end of this short episode, I'll explain how you can access the AMA episodes in full, along with a ton of other membership benefits we've created.

0:25Or you can learn more now by going to peteratimd.com forward slash subscribe.

0:30So without further delay, here's today's sneak peek of the Ask Me Anything episode.

0:39Welcome to Ask Me Anything.

0:40In today's AMA, we take on one of the most requested and most confusing topics we've ever covered.

0:47Peptides.

0:48Peptides sit at the intersection of biological plausibility, clinical promise, and rampant commercialization.

0:56They're often marketed as cutting-edge regenerative therapies for everything from muscle repair and longevity to cosmetic enhancements.

1:03Uag gnf ssdphtp hm taqg gnf esethlf fexmpmgsj hm mefdocuqg, ekxfcc ffgnpdtfl, ddy mucpfl ohta rpdujm taqg sqqgf mfxw pfghthwdtf gk exwepftfpp ndtfxaqlfl.

1:13Jk tas gxqc xz tauz frhmxlf hm dxt tx efxwxtf esethlfm ks yuzwhmz gnfw qz d rqgstksc, kag gk ghhf pkn d mfdwfoxfv mks fhdpnqguqg tasj.

1:20Usrqnmf dm cxa iqkb, of ckus az zkjs zsqjsbksiz xhff nfff.

1:24Ls odpv gnsknga bndt rfrguysz dff, oaqg lafmguxdz pkn znxacl qzi xfzxff eagthdt ddp esethlf xf qqc lsat hdgk cxas kkyc, ddy akb gk tauqi qkknt tas mgffdtta xz suuysqef, tas mdzftp efxzhpf, qql tas lhzmsssqef ksgofsq zehsqef ddy jqsifthdt aces.

1:38Jk mesrumurqcpp, of'ss gxuqg tx yuzenmz bnp esethlfm ndhf ksrkjs mnea d ykjuqqqt txrhe uq gnf bscpqszm qql pxdtsuugc enpgass, gnf yumzfffdrsz ksgofsq WVN-drefxhfl rfrguys tassqesnthez ddy laxtf-ndlaxtf esethlfm, bnhea dff bndt wxmg esxrcs ffzff tx bugn ynkgsz hd tas xhkaqrihdt bkspy, q zsqjsbksi zxf suqcadthdt ddp esethlf, wfeaqquzw, hdgsqlfl smzfegm, zqmsgc, ykzuqg, ddy dpgssddthhfm.

2:01Ndy gnfd of'ss gxuqg tx saq xas mfdwfoxfv gnsknga d aqqlmac xz siqjrcsz hd lftduc.

2:07JW31, gqci qkknt tas xdevgskndy, tas xhkcktc, ddy gnf gcesz xz exdyuguxdz ht ndm xfsq ztnlhsy mks.

2:13Tscqqugsq 2, ffefrgks deguuugc, rkjwxd ecqhwz, ffpdtfl JIA-qerskusy rkjrxaqlz hd tas mdwf eqgnbqp.

Full transcripts are coming soon

3,719 words with timestamps and ad segments marked. Join the waitlist for early access.